ProstaLund

1,87SEK +2,19 %
Vær den første som følger denne virksomhed

ProstaLund operates in medical technology. Today, specialisation is mainly in the area of treatment of benign prostate enlargement (BPH). Through the company CoreTherm, heat treatment of benign prostate enlargement is offered, without the need for surgical operation. The vision is to offer both faster and more efficient solutions against traditional forms of infestation. The company was founded in 1991 and is operating globally, based in Lund.

Omsætning
17,41 mio.
EBIT %
-62,55 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
PLUN
Daglig lav / høj pris
1,81 / 1,885 SEK
Markedsværdi
106,95 mio. SEK
Aktieomsætning
46,89 t SEK
Volumen
25 t

Finanskalender

22% sales growth in the quarter

Selskabsmeddelelse17.05.2023